glp 1 agonist drug interactions GLP-1 receptor agonists show promise in treating substance use disorders Table 2 from Optimizing Outcomes
Description
While utilizing GLP-1Ras in patients with diabetes or underlying cardiovascular disease were demonstrated to have diverse benefits, such as reductions in HbA1c levels, blood pressure control, improving endothelial function, and enhancing the lipid profile [80,81,82], our meta-analysis focused exclusively on weight-related outcomes

FDA approvals for obesity indications have substantially expanded the addressable patient population beyond diabetes, creating unprecedented commercial opportunities

Nausea Real-world studies confirm that nausea is the most frequent GI AE that arises upon initiation of GLP-1 RA [20,43,44]

doi: 10.1097/00041327-199403000-00011

doi: 10.1007/s00125-015-3651-3

Komsuoglu Celikyurt I, Mutlu O, Ulak G, Uyar E, Bekta E, Yildiz Akar F, et al
